Auspex Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people with movement disorders and other rare diseases, including orphan diseases. Its pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington's disease, an orphan disease, tardive dyskinesia and Tourette syndrome in the pediatric population, which is an orphan disease, as well as other orphan indications. Its lead product candidate is SD-809, which is a small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). Its other programs include SD-560, SD-1077 and SD-254.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ASPX
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $94.00
- 200 Day Moving Avg: $59.00
- 52 Week Range: $15.00 - $101.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -50.50
- P/E Growth: 0
- Return on Equity: -61.66%
- Return on Assets: -50.55%
- Average Volume: 634,233 shs.
Frequently Asked Questions for Auspex Pharmaceuticals (NASDAQ:ASPX)
What is Auspex Pharmaceuticals' stock symbol?
Auspex Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASPX."
How were Auspex Pharmaceuticals' earnings last quarter?
Auspex Pharmaceuticals Inc (NASDAQ:ASPX) announced its quarterly earnings data on Monday, March, 16th. The company reported ($0.74) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.15. View Auspex Pharmaceuticals' Earnings History.
Who are some of Auspex Pharmaceuticals' key competitors?
Some companies that are related to Auspex Pharmaceuticals include Amgen (AMGN), Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), Kite Pharma (KITE), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), BeiGene (BGNE), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH) and China Biologic Products (CBPO).
How do I buy Auspex Pharmaceuticals stock?
Shares of Auspex Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Auspex Pharmaceuticals' stock price today?
MarketBeat Community Rating for Auspex Pharmaceuticals (NASDAQ ASPX)MarketBeat's community ratings are surveys of what our community members think about Auspex Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Auspex Pharmaceuticals stock can currently be purchased for approximately $101.00.
Consensus Ratings for Auspex Pharmaceuticals (NASDAQ:ASPX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Auspex Pharmaceuticals (NASDAQ:ASPX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Auspex Pharmaceuticals (NASDAQ:ASPX)Earnings History by Quarter for Auspex Pharmaceuticals (NASDAQ ASPX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Auspex Pharmaceuticals (NASDAQ:ASPX)
Current Year EPS Consensus Estimate: $-4 EPS
Next Year EPS Consensus Estimate: $-2 EPS
Dividend History for Auspex Pharmaceuticals (NASDAQ:ASPX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Auspex Pharmaceuticals (NASDAQ:ASPX)Insider Trades by Quarter for Auspex Pharmaceuticals (NASDAQ:ASPX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/16/2015||David A Stamler||Insider||Sell||3,000||$80.00||$240,000.00|| |
|2/13/2015||Ventures Vii Lp Cmea||Major Shareholder||Sell||122,667||$63.08||$7,737,834.36|| |
|2/11/2015||Ventures Vii Lp Cmea||Major Shareholder||Sell||84,154||$61.06||$5,138,443.24|| |
|2/6/2015||Ventures Vii Lp Cmea||Major Shareholder||Sell||93,179||$59.39||$5,533,900.81|| |
|1/28/2015||Alex Zisson||Director||Sell||730,000||$53.11||$38,770,300.00|| |
|1/28/2015||James E Flynn||Insider||Buy||1,500,000||$56.50||$84,750,000.00|| |
|1/28/2015||Panorama Capital, L.P.||Major Shareholder||Sell||270,000||$53.11||$14,339,700.00|| |
|12/22/2014||David A Stamler||Insider||Sell||2,660||$53.55||$142,443.00|| |
|12/18/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||195,000||$50.14||$9,777,300.00|| |
|10/30/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||19,000||$27.15||$515,850.00|| |
|10/28/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||14,500||$27.02||$391,790.00|| |
|10/27/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||3,413||$27.11||$92,526.43|| |
|10/24/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||16,500||$26.97||$445,005.00|| |
|10/6/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||7,109||$23.45||$166,706.05|| |
|9/19/2014||Gerald T Proehl||Director||Buy||1,466||$21.75||$31,885.50|| |
|9/5/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||25,600||$23.86||$610,816.00|| |
|9/3/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||22,700||$23.08||$523,916.00|| |
|8/28/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||29,600||$22.03||$652,088.00|| |
|8/26/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||6,300||$21.35||$134,505.00|| |
|8/22/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||1,700||$20.56||$34,952.00|| |
|7/16/2014||R Scott Greer||Director||Buy||5,190||$19.25||$99,907.50|| |
|2/10/2014||James E Flynn||Insider||Buy||700,000||$12.00||$8,400,000.00|| |
|2/10/2014||Panorama Capital, L.P.||Major Shareholder||Buy||333,334||$12.00||$4,000,008.00|| |
|2/10/2014||Pratik Shah||CEO||Buy||8,333||$12.00||$99,996.00|| |
|2/10/2014||Sepehr Sarshar||Director||Buy||67,263||$12.00||$807,156.00|| |
Headline Trends for Auspex Pharmaceuticals (NASDAQ:ASPX)
Latest Headlines for Auspex Pharmaceuticals (NASDAQ:ASPX)
Auspex Pharmaceuticals (ASPX) Chart for Friday, July, 21, 2017